Highlights
1 patentProfile claimed by owner
About
Gold Nanoparticles for Cancer Management
Metallo-Therapy (MT) is developing contrast agents that enable precise tumor detection and monitoring using CT imaging. MT's proprietary gold nanoparticles (GNP) accumulate in malignant tumors and remain therefor a few weeks. Due to their low toxicity and contrasting function, the GNPs can function as nano-markers, supporting and enhancing multiple applications in the management of cancer patients undergoing radiotherapy. Metallo-Therapy is supported by the Chief Scientist of the Israeli Ministry of Economy and by Arkin Holdings, an investment fund focused on innovative technologies in the healthcare market.
Identity
| Name | Metallo-Therapy |
|---|---|
| Slug | metallo-therapy |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLCsnIELDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2016 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Nazareth |
| HQ address | Nazareth, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
Simulation & Imaging
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
imagingradiologyhospitalsdetectioncancermedical-technologiesx-raydiagnostics
Funding
| Total raised | $4.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}